08/10/2026
Young people today face growing mental health challenges, and depression remains one of the most common.
This International Youth Day, we're raising awareness about treatment options for adolescents living with major depressive disorder.
For adolescents ages 15–21 who continue to experience depression symptoms, NeuroStar® Advanced Therapy is an FDA-cleared, non-invasive adjunct treatment option. Clinical data show meaningful improvement and remission rates in adolescents treated with NeuroStar.*
Awareness can lead to conversations. Conversations can lead to support. And support can make all the difference. 💜
Schedule a consultation to learn more about NeuroStar TMS therapy.
*1. FDA Clearance K231926 The outcomes reported represent the subset of study patients for which the CGI-S data was reported before and after an acute course of NeuroStar TMS. Patients aged 12 to 21 (average 19.2 ‡ 1.5) were treated under real-world conditions where patients may have been prescribed concomitant depression treatments including medications. "Measurable relief" was defined as a CGI-S score ≤3 and "complete remission" was defined as a CGI-S score ≤2 at the end of treatment.
